Ichor Therapeutics, a pre-clinical biotechnology company located in Syracuse, NY focused on therapeutic interventions for age-related disease, is pleased to announce the addition of William E. Gannon, Jr., MD to the Ichor Science Advisory Board. Dr. Gannon will be advising Ichor on clinical development planning and FDA compliance. His background managing clinical trials and operations as well as the design of corporate and regulatory strategies, regulatory submissions and execution of Phase I through Phase IV clinical trials in the U.S., Europe and Asia will enable him to be a key contributor to Ichor.
Kelsey Moody, Ichor Therapeutics CEO, said “Dr. Gannon’s experience managing clinical trials and leading multinational corporations creates a unique perspective that will help propel Ichor forward.”
Dr. Gannon currently serves as Chief Scientific Officer/Medical Director and Co-Founder of Capital City Technical Consulting (CCTC) a Washington, DC based Consultancy Corporation. He received his medical training and worked in a clinical capacity at Ross University, Case Western Reserve and George Washington University.
Dr. Gannon also obtained an M.B.A. at George Washington University in 1988 and has since built a wealth of experience in the management of clinical trials including designing the trials and building operational teams to ensure their successful completion.
Dr. Gannon has held positions in multinational Clinical Research Organizations, medical device, biotech and pharmaceutical firms. In his most recent position prior to CCTC, Inc., Dr. Gannon served as Vice President – Clinical Medical Affairs in the biotechnology arena.
Dr. Gannon’s primary focus has been on oncology therapeutic and diagnostic applications, but he possesses a broad range of experience across therapeutic categories.